Novartis (NYSE: NVS) today disclosed the first data from its Phase III PSMAddition trial of lutetium‑177...
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement...
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed...
Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...
Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares...
Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...
Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...
CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...
Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...
Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...
Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...